MDT-AP-0038
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 128.04
- os_event
- false
- age_years
- 4.82
- sex
- F
- new_clusters
- C3
- umap1_2d
- 6.178415117
- umap2_2d
- 2.773915957
- umap1_3d
- 2.60216578
- umap2_3d
- -3.086342945
- umap3_3d
- -2.539996089
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.340
- WNT_BETA_CATENIN_SIGNALING+0.270
- HEME_METABOLISM+0.150
- DNA_REPAIR+0.120
- PROTEIN_SECRETION+0.070
- PEROXISOME+0.050
- PI3K_AKT_MTOR_SIGNALING+0.030
- SPERMATOGENESIS-0.010
- FATTY_ACID_METABOLISM-0.020
- ADIPOGENESIS-0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- ANGIOGENESIS-0.510
- ALLOGRAFT_REJECTION-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- INFLAMMATORY_RESPONSE-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.420
- COMPLEMENT-0.400
- COAGULATION-0.390
- KRAS_SIGNALING_UP-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0550 | Med | Medulloblastoma | 0.956 |
| 2 | MDT-AP-1357 | Med | Medulloblastoma | 0.930 |
| 3 | MDT-AP-0578 | Med | Medulloblastoma | 0.924 |
| 4 | MDT-AP-1341 | Med | Medulloblastoma | 0.916 |
| 5 | MDT-AP-0119 | Med | Medulloblastoma | 0.915 |
| 6 | MDT-AP-1138 | Med | Medulloblastoma | 0.910 |
| 7 | SRR1441224 | GTEX | — | 0.903 |
| 8 | SRR820468 | GTEX | — | 0.902 |
| 9 | SRR1490568 | GTEX | — | 0.899 |
| 10 | SRR1322163 | GTEX | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |